DAIC

APRIL 9, 2024

The PROACT study reported no impact on cardiotoxicity biomarkers or secondary endpoints related to heart function among patients who took high doses of enalapril, an ACE inhibitor, along with high doses of anthracyclines. The mean dose of enalapril among those who were randomized to take the ACE inhibitor was 17.7mg.

ACE Inhibitor 105

ACE Inhibitor Cancer Biomarkers Heart Failure 105

NEJM Journal Watch - Cardiology

JANUARY 3, 2024

NEJM Journal Watch reviews over 250 scientific and medical journals to present important clinical research findings and insightful commentary

ACE Inhibitor 75

ACE Inhibitor Research 75

Cardiology Update

AUGUST 4, 2024

This includes beta-blockers, ACE inhibitors, ARBs, ARNIs, MRAs, and SGLT2 inhibitors. The 2021 European Society of Cardiology guidelines recommend guideline-directed medical therapy (GDMT) for patients with HF with reduced ejection fraction (HFrEF).

Heart Failure 119

Heart Failure ACE Inhibitor COVID-19 Quality of Life 119

Heart BMJ

OCTOBER 28, 2024

Resistant hypertension is a condition where blood pressure levels remain elevated above target despite changes in lifestyle and concurrent use of at least three antihypertensive agents, including a long-acting calcium channel blocker (CCB), a blocker of the renin-angiotensin system (ACE inhibitor or angiotensin receptor blocker) and a diuretic.

Hypertension 59

Hypertension ACE Inhibitor Blood Pressure Research 59

Dr. Smith's ECG Blog

NOVEMBER 15, 2023

Contemporary research studies of MINOCA have evaluated the prognosis of these patients, reporting a 12-month all-cause mortality of 4.7% (95% confidence interval, 2.6–6.9), Contemporary research studies of MINOCA have evaluated the prognosis of these patients, reporting a 12-month all-cause mortality of 4.7% (95% confidence interval, 2.6–6.9),

Coronary Angiogram 109

Coronary Angiogram Plaque Thrombosis STEMI 109

Dr. Sanjay Gupta

MARCH 6, 2022

Heart failure is one of the most researched conditions in all of medicine and happily we now have lots of very beneficial therapies which can improve both quality of life and prognosis.

Heart Failure 40

Heart Failure Quality of Life ACE Inhibitor Exercise 40

Dr. Smith's ECG Blog

NOVEMBER 30, 2022

Contemporary research studies of MINOCA have evaluated the prognosis of these patients, reporting a 12-month all-cause mortality of 4.7% (95% confidence interval, 2.6–6.9), Contemporary research studies of MINOCA have evaluated the prognosis of these patients, reporting a 12-month all-cause mortality of 4.7% (95% confidence interval, 2.6–6.9),

Plaque 52

Plaque Chest Pain Thrombosis Stenosis 52